Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Belma Ljutic

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
The Journal of Biological Chemistry|June 19, 2003
Identification of upstream cis-acting regulatory elements controlling lineage-specific expression of the mouse NK cell activation receptor, NKR-P1CBelma Ljutic, James R Carlyle, Juan Carlos Zúñiga-Pflücker
Immunologic Research|September 28, 2006
NKR-P1 biology: from prototype to missing selfAruz Mesci, Belma Ljutic, Andrew P Makrigiannis, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 9, 2005
Functional requirements for signaling through the stimulatory and inhibitory mouse NKR-P1 (CD161) NK cell receptorsBelma Ljutic, James R Carlyle, Dominik Filipp, et al.
Vaccine|March 3, 2012
Formulation, stability and immunogenicity of a trivalent pneumococcal protein vaccine formulated with aluminum salt adjuvantsBelma Ljutic, Martina Ochs, Benjamin Messham, et al.
Immunity|January 16, 2007
Chromosome transfer activates and delineates a locus control region for perforinMatthew E Pipkin, Belma Ljutic, Fernando Cruz-Guilloty, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 6, 2006
Molecular and genetic basis for strain-dependent NK1.1 alloreactivity of mouse NK cellsJames R Carlyle, Aruz Mesci, Belma Ljutic, et al.
Infection and Immunity|April 5, 2012
Neutralizing antibodies elicited by a novel detoxified pneumolysin derivative, PlyD1, provide protection against both pneumococcal infection and lung injuryDanielle Salha, Jason Szeto, Lisa Myers, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2010
Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanomaThorsten U Vogel, Lucian Visan, Belma Ljutic, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
The Journal of Biological Chemistry|June 19, 2003
Identification of upstream cis-acting regulatory elements controlling lineage-specific expression of the mouse NK cell activation receptor, NKR-P1CBelma Ljutic, James R Carlyle, Juan Carlos Zúñiga-Pflücker
Immunologic Research|September 28, 2006
NKR-P1 biology: from prototype to missing selfAruz Mesci, Belma Ljutic, Andrew P Makrigiannis, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 9, 2005
Functional requirements for signaling through the stimulatory and inhibitory mouse NKR-P1 (CD161) NK cell receptorsBelma Ljutic, James R Carlyle, Dominik Filipp, et al.
Vaccine|March 3, 2012
Formulation, stability and immunogenicity of a trivalent pneumococcal protein vaccine formulated with aluminum salt adjuvantsBelma Ljutic, Martina Ochs, Benjamin Messham, et al.
Immunity|January 16, 2007
Chromosome transfer activates and delineates a locus control region for perforinMatthew E Pipkin, Belma Ljutic, Fernando Cruz-Guilloty, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 6, 2006
Molecular and genetic basis for strain-dependent NK1.1 alloreactivity of mouse NK cellsJames R Carlyle, Aruz Mesci, Belma Ljutic, et al.
Infection and Immunity|April 5, 2012
Neutralizing antibodies elicited by a novel detoxified pneumolysin derivative, PlyD1, provide protection against both pneumococcal infection and lung injuryDanielle Salha, Jason Szeto, Lisa Myers, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2010
Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanomaThorsten U Vogel, Lucian Visan, Belma Ljutic, et al.
Pageof 1